Open Orphan - Contract signed with Carna Bioscience
ORPH Mon, 18 Nov 2019, 01:25pm GMT
Open Orphan was founded in 2017, with the goal of becoming Europe’s leading rare disease and orphan drug focused pharma services company by a management team with extensive industry and financial expertise.
Industry: Health Care
Contact: +353 (01) 6440007
Dublin 2, Ireland
Cathal Friel, Chief Executive of Open Orphan is pleased to announce the signing of a contract with Carna Bioscience for a First In Human Clinical pharmacology trial. The contract is expected to deliver significant revenue for the Company over the next twelve months.